Table 3.

Clinical characteristics at baseline of patients with breast cancer and prostate cancer.

Characteristics		Breast cancer (n=74)	Prostate cancer (n=75)	Test statistic	P value
Charlson Comorbidity Scale scorea, median (IQR)		1.0 (1)	3.0 (1)	5082.5b	<.001b
PSAc (at start of treatment), median (range)		N/Ad	5.3 (0-53)
Disease stage (TNMe), n (%)
	T1	N/A	1 (1)
	T1C	N/A	17 (23)
	T2	N/A	11 (15)
	T2A	N/A	1 (1)
	T2B	N/A	7 (9)
	T2C	N/A	7 (9)
	T3	N/A	20 (27)
	T3A	N/A	1 (1)
	T3B	N/A	8 (11)
	Missing	N/A	2 (3)
Histologic grade (Elston-Ellis), n (%)
	Intermediate grade 2	23 (31.1)	N/A
	High grade 3	41 (55.4)	N/A
	Unknown	10 (13.5)	N/A
Tumor characteristicsf, n (%)
	HER2+ ER+ PR+	9 (12.2)	N/A
	HER2+ ER+ PR–	7 (9.5)	N/A
	HER2+ ER– PR–	13 (17.6)	N/A
	HER2– ER+ PR+	16 (21.6)	N/A
	HER2– ER+ PR–	7 (9.5)	N/A
	HER2– ER– PR+	1 (1.4)	N/A
	Triple negative	21 (28.4)	N/A
Proliferation rate (Ki-67), n (%)
	≥ 20 %	72 (97.3)	N/A
	< 20 %	2 (2.7)	N/A
Type of chemotherapy, n (%)
	Anthracyclines, alkylators	3 (4.1)	N/A
	Anthracyclines, alkylators, taxanes	37 (50.0)	N/A
	Anthracyclines, alkylators, antimetabolites, taxanes	9 (12.2)	N/A
	Antimetabolites, alkylators	2 (2.7)	N/A
	Taxanes	11 (14.9)	N/A
	Taxanes, alkylators	1 (1.4)	N/A
	Taxanes, trastuzumab emtansine	2 (2.7)	N/A
	Trastuzumab emtansine	9 (12.2)	N/A
Gleason score, median (range)		N/A	7 (6-9)
Number of radiotherapy treatments, median (range)		N/A	25 (25-29)
Number of neoadjuvant chemotherapy treatments, median (range)		6.0 (2-15)	N/A
Antihormonal treatment, n (%)
	Yes	N/A	55 (73)
	No	N/A	20 (27)
Treatment duration (in weeks), median (range)		15 (3-26)	5 (5-6)

^aA higher value corresponds to greater comorbidity; the score ranges between 0-37.

^bMann-Whitney U test.

^cPSA: Prostate-specific antigen.

^dN/A: not applicable.

^eTNM: Classification of malignant tumors.

^fBreast cancer cell human epidermal growth factor receptor (HER2), estrogen receptor (ER), and progesterone receptor (PR) status.